Parkinson's disease

Overview

Parkinson's disease is a progressive neurodegenerative disorder marked by the loss of dopaminergic neurons in the substantia nigra and the intracellular accumulation of misfolded α-synuclein. It produces the cardinal motor features of bradykinesia, rigidity, resting tremor, and postural instability, alongside a wide range of non-motor manifestations such as cognitive impairment, anxiety, sleep disturbance, autonomic dysfunction, and gastrointestinal symptoms. Aging is its strongest risk factor, and the disease is increasingly understood as heterogeneous, unfolding through prodromal, early, and advanced stages with a diagnostic window in which subtle clinical signs and medication exposures may precede formal diagnosis.

Mechanistically, Parkinson's disease has been linked to mitochondrial dysfunction, oxidative stress driven by reactive oxygen species, neuroinflammation, and impairment of the autophagy-lysosomal system, with genetic contributors such as LRRK2 and PINK1/Parkin implicating mitophagy and protein-clearance defects. Overlapping neurodegenerative biology places it alongside Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, and amyotrophic lateral sclerosis, and much current work focuses on distinguishing these conditions and their mixed pathologies. Microglial transcriptional programs, including markers such as SPP1, characterize the shared neurodegenerative response, while cytoprotective signaling through the KEAP1-NRF2 axis is studied for its role in countering oxidative injury. These insights have made Parkinson's disease a central target for biomarker discovery in large prospective cohorts, for AI-based diagnostic classifiers built on protein and clinical data, for pharmacoepidemiological studies of risk-modifying exposures, and for the development of disease-modifying and device-aided symptomatic therapies.

Recent Publications Summary

Recent publications on Parkinson's disease (PD) focused heavily on biomarker discovery, prediagnostic clinical patterns, and computational approaches to diagnosis and drug repurposing. The EPIC4ND case-cohort study was introduced as a large prospective resource within the European Prospective Investigation into Cancer and Nutrition cohort, designed to identify biomarkers predicting future onset of PD and other neurodegenerative diseases; it includes 610 incident PD cases, 72 prevalent PD cases, and 118 incident Parkinsonism cases, with multi-omics data generated from pre-disease blood samples 42484778Jul. In parallel, a nationwide claims-based case-control study in Taiwan examined clinical associations and medication exposures during the year before PD diagnosis, aiming to better characterize the diagnostic window in real-world care and to assess secondary neurological outcomes and all-cause mortality during follow-up 42261249Jun.

Several studies applied artificial intelligence and graph-based methods to PD-related gene discovery and diagnosis. A prototype-augmented graph representation learning framework (MOGT) was used to predict disease-associated genes across neurodegenerative and psychiatric disorders; for PD, high-risk genes predicted by the model were integrated with the CMAP database to identify 10 candidate drugs, and one compound, UK-356618, was experimentally validated in a primary neuron model to reverse abnormal expression of PD-associated genes and improve cell-level phenotypes 42213730May. Another study developed a generalizable protein-based AI classifier using the NULISA CNS panel to classify PD alongside Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, and healthy controls, with the stated goal of improving diagnosis and disentangling mixed pathologies 42050390Apr. A separate modular deep learning framework for interpretable disease prediction was also evaluated on a Parkinson's disease dataset as part of broader benchmarking across heterogeneous clinical datasets 42102106May. In addition, a Viewpoint describing the AI-PROGNOSIS project noted the use of governance frameworks for predictive models and digital biomarkers intended to support PD diagnosis and care 42054664Apr.

Other publications addressed PD within broader neurodegeneration biology. A cross-disease microglial transcriptional analysis included Parkinson's disease among several neurodegenerative conditions and identified a shared microglial transcriptional program associated with inflammatory and neurodegenerative processes, with machine learning able to discriminate neurodegenerative from control samples 42011986Apr. A pan-neurodegeneration proteomics atlas spanning 2,279 human brain samples included PD and reported disease subtypes, dysregulated pathways, and shared alterations across neurodegenerative diseases, including proteins linked to microglial and lysosomal activation and synaptic regulation 41875888Mar. A review on energy compensation strategies for neurodegenerative disease also discussed PD in the context of mitochondrial dysfunction, protein homeostasis imbalance, and metabolic disorders, outlining approaches such as enhancing mitochondrial function, systemic metabolic remodeling, alternative energy substrates, and direct energy delivery technologies 41818703Mar.

One pharmacoepidemiologic study specifically tested a previously reported signal for furosemide and PD risk. In a Finnish nationwide nested case-control study, furosemide use was not associated with PD risk in the main analysis using a 3-year lag, although a borderline statistically significant association was observed when comparing risk across categories of cumulative exposure 42168783May. Another report described severe dysphagia after COVID-19 vaccination in two cases, including an 80-year-old man with PD who developed aspiration pneumonia and dysphagia; the authors noted that dysphagia following vaccination is very rare and advised clinicians to be aware of possible appearance or worsening of swallowing difficulties 41224265Nov.

What Changes, What Holds

1. biomarker work now points to prediagnostic blood signatures and a clearer diagnostic window
METHOD The new studies extend the biomarker and prodromal framing already in the Overview by showing how large prospective cohorts and claims data can be used to search for signals before formal diagnosis and to map the year before diagnosis in routine care 42484778Jul42261249Jun. They do not overturn the baseline account, but they sharpen the practical idea that PD can be studied and perhaps detected before classic motor recognition.

2. AI is becoming a practical tool for PD classification and drug repurposing, not just a research add-on
METHOD These papers strengthen the Overview’s point that AI-based diagnostic classifiers and computational discovery are now central to PD research, while also showing a more translational use: gene-prioritization models feeding directly into candidate drug selection and experimental validation 42213730May42050390Apr. The established account stands, but the work suggests the field is moving from prediction toward actionable classification and repurposing pipelines.

3. Shared neurodegenerative biology in PD is being mapped more deeply across cells, proteins, and metabolism
REINFORCES The new analyses reinforce the Overview’s emphasis on overlapping neurodegenerative biology, microglial programs, mitochondrial dysfunction, and lysosomal/protein-clearance defects by adding cross-disease transcriptional and proteomic evidence plus a metabolic framing 42011986Apr41875888Mar41818703Mar. Nothing here displaces the baseline; instead, it broadens the molecular context in which PD sits alongside other neurodegenerative disorders.

4. The furosemide signal weakens, while swallowing problems after vaccination remain a rare adverse event rather than a PD mechanism
NEW DIRECTION The Finnish study cuts against a previously reported medication-risk association by failing to support furosemide as a PD risk factor in the main analysis, so the exposure signal remains unsettled and likely needs replication in other designs 42168783May. The vaccination case report adds a separate harm signal in a patient with PD, but the Overview says nothing about vaccine-related swallowing outcomes, so this is an adverse-event observation, not a contradiction 41224265Nov.

Overview update candidates: prediagnostic biomarker discovery and characterization of the diagnostic window; AI-assisted diagnosis; mixed-pathology classification; and computational drug repurposing; shared microglial and proteomic signatures across neurodegeneration.